---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-062068"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:47:01.171416+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics reports FY2022 net loss $250.2M, SER-109 PDUFA date April 26, 2023

## Summary
- FY2022 net loss $250.2M vs $65.6M in FY2021; Q4 net loss $68.8M vs $50.0M.
- Cash & equivalents $181.3M at Dec 31, 2022, down from $291.2M at end of 2021.
- SER-109 BLA under FDA priority review with PDUFA target action date April 26, 2023; commercial launch anticipated soon after.
- SER-155 Phase 1b: cohort 2 enrollment ongoing; initial safety/pharmacology data from cohort 1 expected May 2023.
- Pending FDA approval, Seres expects $125M milestone payment from Nestlé Health Science.

## SEC filing metadata
- accession: 0001193125-23-062068
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/0001193125-23-062068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/d448387d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-062068
- JSON: https://secwatch.observer/filing/0001193125-23-062068.json
- Plain text: https://secwatch.observer/filing/0001193125-23-062068.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.
  - Period: quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 7, 2023, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and provided operational updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312523062068/0001193125-23-062068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.